ERG oncogene modulates prostaglandin signaling in prostate cancer cells

References

• Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005; 24:3847 - 3852
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310:644 - 648
   PubMed Web of Science ®Google Scholar
• Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8:497 - 511
   PubMed Web of Science ®Google Scholar
• Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26:4596 - 4599
   PubMed Web of Science ®Google Scholar
• Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008; 27:5348 - 5353
   PubMed Web of Science ®Google Scholar
• Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009; 69:1400 - 1406
   PubMed Web of Science ®Google Scholar
• Rostad K, Mannelqvist M, Halvorsen OJ, Oyan AM, Bo TH, Stordrange L, et al. ERG upregulation and related ETS transcription factors in prostate cancer. Int J Oncol 2007; 30:19 - 32
   PubMed Web of Science ®Google Scholar
• Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007; 31:882 - 888
   PubMed Web of Science ®Google Scholar
• Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008; 68:3584 - 3590
   PubMed Web of Science ®Google Scholar
• Hu Y, Dobi A, Sreenath T, Cook C, Tadase AY, Ravindranath L, et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 2008; 14:4719 - 4725
   Google Scholar
• Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, et al. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res 2009; 69:2734 - 2738
   PubMed Web of Science ®Google Scholar
• Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008; 21:67 - 75
   PubMed Web of Science ®Google Scholar
• Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 2009; 11:804 - 811
   Google Scholar
• Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41:619 - 624
   PubMed Web of Science ®Google Scholar
• Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 2008; 105:2105 - 2110
   PubMed Web of Science ®Google Scholar
• Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci USA 2009; 106:12465 - 12470
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10:177 - 188
   PubMed Web of Science ®Google Scholar
• King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009; 41:524 - 526
   PubMed Web of Science ®Google Scholar
• Tai HH, Cho H, Tong M, Ding Y. NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions.. Curr Pharm Des 2006; 12:955 - 962
   PubMed Web of Science ®Google Scholar
• Heighway J, Knapp T, Boyce L, Brennand S, Field JK, Betticher DC, et al. Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 2002; 21:7749 - 7763
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007; 282:11613 - 11617
   PubMed Web of Science ®Google Scholar
• Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA 2006; 103:12098 - 12102
   PubMed Web of Science ®Google Scholar
• Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, et al. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006; 66:7818 - 7823
   PubMed Web of Science ®Google Scholar
• Wang D, DuBois RN. Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett 2008; 267:197 - 203
   PubMed Web of Science ®Google Scholar
• Chaudry AA, Wahle KW, McClinton S, Moffat LE. Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer 1994; 57:176 - 180
   PubMed Web of Science ®Google Scholar
• Ma X, Kundu N, Rifat S, Walser T, Fulton AM. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 2006; 66:2923 - 2927
   PubMed Web of Science ®Google Scholar
• Quidville V, Segond N, Lausson S, Frenkian M, Cohen R, Jullienne A. 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line. Prostaglandins Other Lipid Mediat 2006; 81:14 - 30
   PubMed Web of Science ®Google Scholar
• Frenkian M, Segond N, Pidoux E, Cohen R, Jullienne A. Indomethacin, a COX inhibitor, enhances 15-PGDH and decreases human tumoral C cells proliferation. Prostaglandins 2001; 65:11 - 20
   PubMed Web of Science ®Google Scholar
• Chi X, Freeman BM, Tong M, Zhao Y, Tai HH. 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is upregulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells. Arch Biochem Biophys 2009; 487:139 - 145
   PubMed Web of Science ®Google Scholar
• Tseng-Rogenski S, Lee IL, Gebhardt D, Fischer SM, Wood C, Park JM, et al. Loss of 15-hydroxyprostaglandin dehydrogenase expression disrupts urothelial differentiation. Urology 2008; 71:346 - 350
   PubMed Web of Science ®Google Scholar
• Eruslanov E, Kaliberov S, Daurkin I, Kaliberova L, Buchsbaum D, Vieweg J, et al. Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. J Immunol 2009; 182:7548 - 7557
   PubMed Web of Science ®Google Scholar
• De Marzo AM, Nakai Y, Nelson WG. Inflammation, atrophy and prostate carcinogenesis. Urol Oncol 2007; 25:398 - 400
   PubMed Web of Science ®Google Scholar
• Greenland KJ, Jantke I, Jenatschke S, Bracken KE, Vinson C, Gellersen B. The human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase gene promoter is controlled by Ets and activating protein-1 transcription factors and progesterone. Endocrinology 2000; 141:581 - 597
   PubMed Web of Science ®Google Scholar
• Nandy A, Jenatschke S, Hartung B, Milde-Langosch K, Bamberger AM, Gellersen B. Genomic structure and transcriptional regulation of the human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase gene. J Mol Endocrinol 2003; 31:105 - 121
   PubMed Web of Science ®Google Scholar
• Lee KS, Lee HJ, Ahn KS, Kim SH, Nam D, Kim DK, et al. Cyclooxygenase-2/prostaglandin E2 pathway mediates icariside II induced apoptosis in human PC-3 prostate cancer cells. Cancer Lett 2009; 280:93 - 100
   PubMed Web of Science ®Google Scholar
• Ahmad A, Kong D, Wang Z, Sarkar SH, Banerjee S, Sarkar FH. Downregulation of uPA and uPAR by 3,3′-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells. J Cell Biochem 2009; 108:916 - 925
   PubMed Web of Science ®Google Scholar
• Noskova V, Ahmadi S, Asander E, Casslen B. Ovarian cancer cells stimulate uPA gene expression in fibroblastic stromal cells via multiple paracrine and autocrine mechanisms. Gynecol Oncol 2009; 115:121 - 126
   PubMed Web of Science ®Google Scholar
• Chen Y, Hughes-Fulford M. Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. Br J Cancer 2000; 82:2000 - 2006
   PubMed Web of Science ®Google Scholar
• Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66:8337 - 8341
   PubMedGoogle Scholar
• Nam RK, Sugar L, Wang Z, Yang W, Kitching R, Klotz LH, et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007; 6:40 - 45
   PubMed Web of Science ®Google Scholar
• Shin S, Kim TD, Jin F, van Deursen JM, Dehm SM, Tindall DJ, et al. Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res 2009; 69:8102 - 8110
   PubMed Web of Science ®Google Scholar
• Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, et al. An integrated network of androgen receptor, poly-comb and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17:443 - 454
   PubMed Web of Science ®Google Scholar
• Hawcroft G, Ko CW, Hull MA. Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells. Oncogene 2007; 26:3006 - 3019
   Google Scholar
• De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7:256 - 269
   PubMed Web of Science ®Google Scholar
• Otani T, Yamaguchi K, Scherl E, Du B, Tai HH, Greifer M, et al. Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNFalpha. Am J Physiol Gastrointest Liver Physiol 2006; 290:361 - 368
   Web of Science ®Google Scholar
• Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 2010; 13:228 - 237
   PubMed Web of Science ®Google Scholar
• Mohamed AA, Tan SH, Mikhalkevich N, Ponniah S, Vasioukhin V, Bieberich CJ, et al. Ets family protein, ERG expression in developing and adult mouse tissues by a highly specific monoclonal antibody. Journal of Cancer 2010; 1:197 - 208
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402 - 408
   PubMed Web of Science ®Google Scholar
• Masuda K, Werner T, Maheshwari S, Frisch M, Oh S, Petrovics G, et al. Androgen receptor binding sites identified by a GREF_GATA model. J Mol Biol 2005; 353:763 - 771
   PubMedGoogle Scholar